Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2015’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview 10
Therapeutics Development 11
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 11
Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis 12
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies 13
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes 16
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies 21
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes 24
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 25
Aeolus Pharmaceuticals, Inc. 25
Bolder Biotechnology, Inc. 26
Cantex Pharmaceuticals, Inc. 27
Cellerant Therapeutics, Inc. 28
Cleveland BioLabs, Inc. 29
Gamida Cell Ltd. 30
Humanetics Corporation 31
Meabco A/S 32
NeoStem, Inc. 33
Neumedicines Inc. 34
Onconova Therapeutics, Inc. 35
Piramal Enterprises Limited 36
Pluristem Therapeutics Inc. 37
Priaxon AG 38
ProCertus BioPharm Inc. 39
RDD Pharma Ltd. 40
RxBio, Inc. 41
Soligenix, Inc. 42
Terapio Corporation 43
Tonix Pharmaceuticals Holding Corp. 44
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
517-PXN - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AEOL-10171 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
BBT-007 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
BBT-015 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
BBT-018 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BBT-045 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
BCN-057 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BIO-300 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BP-C2 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CLT-009 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
EDL-2000 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
entolimod - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
EWA-001 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
GC-003 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
GC-4403 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
GC-4419 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
JP4-039 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
NMIL-121 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
P-276 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
PGX-100 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
PLX-RAD - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
PrC-210 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
recilisib sodium - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute radiation syndrome and Ischemic organ injury - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
romyelocel-L - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
RP-239X - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
rusalatide acetate - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Rx-100 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
RX-101 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
SGX-201 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecule for Radiation Proctitis - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecules for Radiation and Chemical Toxicity - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecules for Radiation Toxicity - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
ST-7 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Stem Cell Therapy for Radiation Exposure - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
SY-303A - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
SY-513 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
TPO-7630 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Recent Pipeline Updates 108
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 120
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 123
Featured News & Press Releases 123
Jan 12, 2015: Cleveland BioLabs Receives Department of Defense Support to Further Development of Entolimod as a Medical Radiation Countermeasure 123
Sep 11, 2014: Cellerant Awarded $47.5 Million Under Existing U.S. Government Contract to Support Development of CLT-008 123
Sep 03, 2014: Cleveland BioLabs Announces Green Light to Submit Pre-Emergency Use Authorization Application for Entolimod 124
Apr 18, 2014: Neumedicines Publishes Clinical Data Demonstrating Safety and Hematopoietic and Immune Effects of HemaMax (rHuIL-12), a Radiation Medical Countermeasure 125
Apr 15, 2014: Neumedicines Announces Publication of Phase II-Equivalent Data Demonstrating the Survival Effect of HemaMax (rHuIL-12), a Radiation Medical Countermeasure 126
Feb 25, 2014: Humanetics Enters Into Cooperative Research and Development Agreement With the U.S. Army Medical Research Institute of Chemical Defense 127
Feb 03, 2014: U.S. National Institutes of Health to Commence New Study of Pluristem's PLX Cells for Acute Radiation Syndrome Treatment 127
Jan 23, 2014: Cleveland BioLabs Provides Update on Barda Development Proposal 128
Jan 09, 2014: Neumedicines to Feature HemaMax Study Results in Presentation at Biotech Showcase Conference 128
Dec 13, 2013: Neumedicines Presents HemaMax Clinical Data at the ASH Conference 129
Appendix 131
Methodology 131
Coverage 131
Secondary Research 131
Primary Research 131
Expert Panel Validation 131
Contact Us 131
Disclaimer 132
List Of Tables
List of Tables
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2015 11
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Late Stage Development, H1 2015 17
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Development, H1 2015 19
Comparative Analysis by Unknown Stage Development, H1 2015 20
Products under Development by Companies, H1 2015 21
Products under Development by Companies, H1 2015 (Contd..1) 22
Products under Development by Companies, H1 2015 (Contd..2) 23
Products under Investigation by Universities/Institutes, H1 2015 24
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 25
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H1 2015 26
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 27
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H1 2015 28
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H1 2015 29
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Gamida Cell Ltd., H1 2015 30
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H1 2015 31
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H1 2015 32
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by NeoStem, Inc., H1 2015 33
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H1 2015 34
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H1 2015 35
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Piramal Enterprises Limited, H1 2015 36
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H1 2015 37
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Priaxon AG, H1 2015 38
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ProCertus BioPharm Inc., H1 2015 39
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd., H1 2015 40
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H1 2015 41
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H1 2015 42
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H1 2015 43
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 44
Assessment by Monotherapy Products, H1 2015 45
Number of Products by Stage and Target, H1 2015 47
Number of Products by Stage and Mechanism of Action, H1 2015 49
Number of Products by Stage and Route of Administration, H1 2015 51
Number of Products by Stage and Molecule Type, H1 2015 53
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics - Recent Pipeline Updates, H1 2015 108
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2015 120
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..1), H1 2015 121
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..2), H1 2015 122
List Of Figures
List of Figures
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2015 11
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 18
Comparative Analysis by Early Stage Products, H1 2015 19
Assessment by Monotherapy Products, H1 2015 45
Number of Products by Top 10 Targets, H1 2015 46
Number of Products by Stage and Top 10 Targets, H1 2015 46
Number of Products by Top 10 Mechanism of Actions, H1 2015 48
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 48
Number of Products by Top 10 Routes of Administration, H1 2015 50
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 51
Number of Products by Top 10 Molecule Types, H1 2015 52
Number of Products by Stage and Top 10 Molecule Types, H1 2015 52
